In early April, the Russian Ministry of Health recorded the world’s first distinct immunoglobulin for the Corona virus on the basis of the blood plasma of people recovering from the disease
The Russian Federal Biomedical Agency announced that the drug “Covid globulin”, the first registered immune drug in the world, is currently undergoing clinical trials.
“The first phase of clinical trials of a drug prepared in the laboratory of the Rostec Corporation Immuno-Natsymbio Corporation, which is a unique anti-Covid immunoglobulin, is taking place,” Olga Eichler, head of the medical support department at the Russian Federal Biomedical Agency, said in a statement on the sidelines of the East Economic Forum. , according to Russian media.
In early April, the Russian Ministry of Health recorded the world’s first distinct immunoglobulin for the Corona virus, based on the blood plasma of people recovering from the disease.
After the completion of the second and third phases of clinical trials, it is expected that the drug will be used in the treatment of moderate and severe cases of Covid-19 infection.
The Corona virus has caused the death of at least 4,565,622 people in the world since the World Health Organization office in China reported the emergence of the disease at the end of December 2019.
At least 220,652,860 people have been confirmed to have contracted the virus since its appearance. The vast majority of those infected recovered, although some continued to experience symptoms weeks or even months later.
The figures are based on daily reports issued by each country’s health authorities and exclude subsequent reviews by statistical agencies that indicate much higher death numbers.
The World Health Organization, taking into account the excess mortality rate directly or indirectly related to Covid-19, considers that the outcome of the epidemic may be two or three times greater than the officially announced outcome.